A new trial offers hope for those with advanced prostate cancer.
Checkpoint inhibitors, in particular, are a type of drug that works by taking the “brakes” off of the immune system, releasing its T cells to attack cancer cells.
In prostate cancer, however, previous trials have suggested that immunotherapy does not work. But a new study examines the genetic makeup of prostate cancer tumors and shows that this approach singles out a group of patients for which the therapy might actually work.
In fact, the trial shows that 1 in 10 men who were failed by all other types of treatment have benefited from the checkpoint inhibitor drug pembrolizumab, and that for many of these patients, the benefits are still showing after a year.
The trial was carried out by researchers at the Institute of Cancer Research in collaboration with those at the Royal Marsden NHS Foundation Trust — both in London, the United Kingdom.
The results were presented at the annual meeting of the American Society of Clinical Oncology, held in Chicago, IL.
BRCA mutations easier to target
During this trial, the researchers administered pembrolizumab to 258 men with advanced prostate cancer.
Of these, 38 percent survived for a year, and 11 percent are still taking the drug a year after the trial ended, with no signs of their cancer advancing.
Some of these patients experienced significant remission. For 5 percent of the patients, the tumors got smaller or disappeared completely.
Though this percentage may seem small, the response rate was much higher in people whose tumors had mutations in their DNA-repairing genes, such as BRCA mutations.
Although the researchers do not yet know why this subset of patients benefited so much more from immunotherapy, they do have a hypothesis.
In fact, they believe that these highly mutated cancer cells might be easier to identify and target by the immune system because they look so different from normal cells.
In future trials, the scientists are planning to test the effect of the checkpoint inhibitor in men with DNA-repairing gene mutations.
For now, the scientists compared the effects of pembrolizumab in patients whose prostate tumors were covered in a protein called PD-L1 with those who did not have this protein.
The reseachers found that examining PD-L1 levels was not enough to predict which patients would respond to immunotherapy; instead, they found clues that another protein called PD-L2 may be a better predictor.
Prof. Johann de Bono, who is the director of the Drug Development Unit at the Institute of Cancer Research, comments on the findings.
He says, “In the last few years immunotherapy has changed the way we treat many advanced cancers — but up to now no one had demonstrated a benefit in men with prostate cancer.”
“Our study has found that immunotherapy can benefit a subset of men with advanced, otherwise untreatable prostate cancer, and these are most likely to include patients who have specific DNA repair mutations within their tumors.”
Prof. Johann de Bono
“We are planning a new clinical trial, specifically in men with prostate cancer whose tumors have mutations in DNA repair genes, to see if immunotherapy can become a standard part of their treatment,” he adds.
“It’s exciting that immunotherapy could offer some men more time with their loved ones where they have such advanced disease that they have run out of existing treatment options,” concludes Prof. de Bono.